Alleviant Medical develops a no-implant shunt therapy designed to alleviate the clinical and economic burden of heart failure. The Alleviant System, which has received Breakthrough Device Designation from the U.S. FDA, aims to improve patient outcomes and reduce healthcare costs associated with heart failure management.

Atalanta Therapeutics is developing di-siRNA technology to utilize RNA interference for gene silencing, targeting the underlying mechanisms of neurodegenerative diseases such as Huntington's disease. This approach aims to provide effective treatment options that address the urgent need for interventions in central nervous system disorders.

Avalyn Pharma develops inhaled formulations of anti‑fibrotic drugs, such as pirfenidone (AP01), delivered via a handheld eFlow® nebulizer that targets the lung directly. This lung‑focused delivery enables lower systemic doses, reducing side effects and improving patient adherence while aiming to stabilize lung function in progressive interstitial lung diseases.

Bluejay Therapeutics is developing monoclonal antibodies targeting chronic viral infections, specifically focusing on chronic hepatitis D and B. The company aims to provide effective treatment options that achieve high virologic response rates, addressing the unmet need for cures in infectious liver diseases.

Bonum Therapeutics develops a novel class of regulated protein therapeutics using an antibody-based mechanism for targeted drug delivery. These therapeutics remain inactive until bound to a specific target, activating potent biological activity only where needed. The company is currently focused on developing antibody-controlled cytokine-based therapeutics for cancer treatment.

Engrail Therapeutics develops precision-targeted therapeutics for patients with life-limiting neurological disorders by leveraging expertise in molecular mechanisms and neurocircuitry. The company aims to provide effective treatments that address the unmet medical needs of individuals suffering from these debilitating conditions.

ER Ocean Recherche creates marine‑derived textile materials such as SeiFibre™, SeiYarn™ and SeiShell™ by converting algae, cyanobacteria and seafood shell waste into fibers, yarns and coatings. Their low‑impact, plastic‑free process delivers high‑performance, scalable fabrics that are validated as finished garments for fashion brands, while supporting blue‑carbon initiatives and open collaboration with textile manufacturers.

Provides a finance-specific AI-powered search engine that leverages hybrid search models and specialized embeddings to deliver hyper-accurate insights for equity research. This tool enables hedge funds and asset managers to quickly identify relevant data, trends, and cross-sector impacts, improving decision-making and productivity during critical analysis periods like earnings reports.

Maxwell Biomedical is developing the Spatial Resynchronization Therapy (SRT) System, a non-ablative device that employs ultra-low energy stimulation to restore functional sinus rhythm in patients with atrial fibrillation and heart failure. This technology continuously monitors cardiac activity to prevent AF episodes and improve left atrial function, addressing the increased risks of stroke and heart failure associated with these conditions.

Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.

OncoResponse is developing monoclonal antibodies that target immunosuppressive myeloid cells in the tumor microenvironment, utilizing immune responses from patients who have achieved exceptional outcomes with checkpoint inhibitor therapies. This approach aims to convert cold tumors into hot tumors, enhancing immune activity against cancer.

Oxa develops an autonomous software platform that enables any vehicle to operate in a self-driving capacity across diverse environments, enhancing operational efficiency and safety. By providing organizations with the tools to deploy self-driving technology, Oxa addresses the challenges of transportation cost and complexity in various industries.

Rem provides an AI-driven platform that automates commission management and enhances quoting and enrollment processes for insurance producers. By streamlining operations and delivering personalized customer experiences, the platform reduces operational costs and increases revenue potential for agencies and carriers.

SeQure Dx provides analytical tools that evaluate on-target specificity and off-target risks in CRISPR gene editing therapies, ensuring safety throughout the development process. By delivering precise safety data, the company addresses concerns about unintended genomic alterations that could impact patient outcomes and regulatory compliance.

Sparrow Pharmaceuticals is developing clofutriben, a selective HSD-1 inhibitor, to reduce excess intracellular cortisol in patients with endocrine disorders such as Cushing’s syndrome and autonomous cortisol secretion. The company is also advancing SPI-47, a combination therapy aimed at treating polymyalgia rheumatica with the therapeutic efficacy of glucocorticoids while minimizing severe side effects.

Wugen is developing off-the-shelf allogeneic cellular therapies, including CAR-T and NK cell treatments, specifically targeting solid tumors and hematologic malignancies. These therapies aim to provide effective treatment options for patients with relapsed or refractory cancers, utilizing engineered cells derived from healthy donors to enhance therapeutic efficacy.

Xilio Therapeutics develops tumor-activated immuno-oncology therapies using proprietary platform technology to create targeted molecules that enhance anti-tumor activity within the tumor microenvironment. This approach aims to provide effective treatment options for patients with solid tumors while minimizing systemic side effects associated with traditional immuno-oncology therapies.